Cookie preferences
This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the comfort when using this website, are used for direct advertising or to facilitate interaction with other websites and social networks, are only set with your consent.
Configuration
Technically required
These cookies are necessary for the basic functions of the shop.
"Allow all cookies" cookie
"Decline all cookies" cookie
CSRF token
Cookie preferences
Currency change
Customer-specific caching
FACT-Finder tracking
Individual prices
Selected shop
Session
Comfort functions
These cookies are used to make the shopping experience even more appealing, for example for the recognition of the visitor.
Note
Show the facebook fanpage in the right blod sidebar
Statistics & Tracking
Affiliate program
Conversion and usertracking via Google Tag Manager
Track device being used
![Lucitanib (hydrochloride)](https://www.biomol.com/media/image/bc/c8/03/Cay37711-1_600x600.png)
If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
Lucitanib is a dual inhibitor of VEGFR and FGFR that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50s =... more
Product information "Lucitanib (hydrochloride)"
Lucitanib is a dual inhibitor of VEGFR and FGFR that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50s = 7, 25, and 10 nM, respectively) and FGFR1 and FGFR2 (IC50s = 17.5 and 82.5 nM, respectively). It is selective for these receptors over FGFR3 and FGFR4 (IC50s = 237.5 and >1,000 nM, respectively), as well as the PDGFR family members c-Kit, PDGFRalpha, and PDGFRbeta (IC50s = 456, 175, and 525 nM, respectively), but does inhibit FMS, also known as CSF-1 receptor tyrosine kinase (IC50 = 5 nM). Lucitanib inhibits the proliferation of human umbilical vein endothelial cells (HUVECs) induced by VEGF or basic FGF (bFGF, IC50s = 40 and 50 nM, respectively) but inhibits the proliferation of A2780 ovarian, A498 renal, and SN12KI renal cancer cells only at higher concentrations (IC50s = 27.7, 19.6, and 12.79 µM, respectively). It reduces tumor growth in HT-29 colon and A2780 ovarian cancer mouse xenograft models, as well as in RXF 393, A498, and SKN12I renal cancer mouse xenograft models in a dose-dependent manner. It also completely inhibits bFGF-induced angiogenesis in a Matrigel(TM) plug assay in mice when administered at a dose of 20 mg/kg.Formal Name: 6-[[7-[(1-aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl]oxy]-N-methyl-1-naphthalenecarboxamide, dihydrochloride. CAS Number: 2108875-91-6. Synonyms: AL 3810, E-3810. Molecular Formula: C26H25N3O4 . 2HCl. Formula Weight: 516.4. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: Slightly Soluble, DMSO: 5 mg/ml, Ethanol: Slightly Soluble, PBS (pH 7.2): Slightly Soluble. SMILES: O=C(C1=CC=CC2=CC(OC3=CC=NC4=C3C=C(OC)C(OCC5(CC5)N)=C4)=CC=C21)NC.Cl.Cl. InChi Code: InChI=1S/C26H25N3O4.2ClH/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26,,/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30),2*1H. InChi Key: GJYKJPXOPZOBBC-UHFFFAOYSA-N.
Keywords: | AL 3810, E-3810, 6-[[7-[(1-aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl]oxy]-N-methyl-1-naphthalenecarboxamide, dihydrochloride |
Supplier: | Cayman Chemical |
Supplier-Nr: | 37711 |
Properties
Application: | VEGFR / FGFR dual inhibitor |
MW: | 516.4 D |
Formula: | C26H25N3O4 . 2HCl |
Purity: | >95% |
Format: | Crystalline Solid |
Database Information
CAS : | 2108875-91-6| Matching products |
KEGG ID : | K05096 | Matching products |
Handling & Safety
Storage: | -20°C |
Shipping: | -20°C (International: -20°C) |
Caution
Our products are for laboratory research use only: Not for administration to humans!
Our products are for laboratory research use only: Not for administration to humans!
Information about the product reference will follow.
more
You will get a certificate here
Viewed